Nikhil Wagle - Publications

Affiliations: 
 

161 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, ... ... Wagle N, et al. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. Jco Precision Oncology. 6: e2100413. PMID 35797509 DOI: 10.1200/PO.21.00413  0.578
2022 Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, et al. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications. 13: 2011. PMID 35440136 DOI: 10.1038/s41467-022-29498-9  0.35
2022 Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, ... ... Wagle N, et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Research. PMID 35078818 DOI: 10.1158/0008-5472.CAN-21-2576  0.389
2021 Qi M, Nayar U, Ludwig LS, Wagle N, Rheinbay E. cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. Bmc Bioinformatics. 22: 611. PMID 34952565 DOI: 10.1186/s12859-021-04529-2  0.578
2021 Alcon C, Gómez Tejeda Zañudo J, Albert R, Wagle N, Scaltriti M, Letai A, Samitier J, Montero J. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells. 10. PMID 34359829 DOI: 10.3390/cells10071659  0.323
2021 Balch SM, Vaz-Luis I, Li T, Tayob N, Jain E, Helvie K, Buendia-Buendia JE, Shannon E, Isakoff SJ, Tung NM, Krop IE, Lin NU, Wagle N, Freedman RA. A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment. PMID 34302589 DOI: 10.1007/s10549-021-06329-x  0.303
2021 Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, ... ... Wagle N, et al. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Journal of the National Comprehensive Cancer Network : Jnccn. 1-8. PMID 33761455 DOI: 10.6004/jnccn.2020.7662  0.306
2020 Garrido-Castro AC, Spurr LF, Hughes ME, Li YY, Cherniack AD, Kumari P, Lloyd MR, Bychkovsky B, Barroso-Sousa R, Di Lascio S, Jain E, Files JL, Mohammed-Abreu A, Krevalin M, MacKichan C, ... ... Wagle N, et al. Genomic characterization of de novo metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33293374 DOI: 10.1158/1078-0432.CCR-20-1720  0.302
2020 Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, Wagle N, Stenzinger A, Bonastre J, Bayle A, Michiels S, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32853681 DOI: 10.1016/J.Annonc.2020.07.014  0.451
2020 Mao P, Cohen O, Kowalski KJ, Kusiel J, Buendia-Buendia JE, Cuoco MS, Exman P, Wander SA, Waks AG, Nayar U, Chung JH, Freeman SS, Rozenblatt-Rosen O, Miller VA, Piccioni F, ... ... Wagle N, et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32723837 DOI: 10.1158/1078-0432.Ccr-19-3958  0.669
2020 Slyper M, Porter CBM, Ashenberg O, Waldman J, Drokhlyansky E, Wakiro I, Smillie C, Smith-Rosario G, Wu J, Dionne D, Vigneau S, Jané-Valbuena J, Tickle TL, Napolitano S, Su MJ, ... ... Wagle N, et al. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nature Medicine. 26: 792-802. PMID 32405060 DOI: 10.1038/S41591-020-0844-1  0.373
2020 Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, ... ... Wagle N, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery. PMID 32404308 DOI: 10.1158/2159-8290.Cd-19-1390  0.766
2020 Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Janne PA, et al. Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32312893 DOI: 10.1158/1078-0432.Ccr-20-0397  0.357
2020 Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, ... ... Wagle N, et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32245699 DOI: 10.1016/J.Annonc.2020.02.008  0.476
2020 Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, ... ... Wagle N, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32170028 DOI: 10.1158/1078-0432.Ccr-19-3005  0.39
2020 Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, Lin N, Tolaney SM, Wagle N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 387-394. PMID 32067680 DOI: 10.1016/J.Annonc.2019.11.010  0.488
2020 Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gómez Tejeda Zañudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, ... ... Wagle N, et al. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nature Medicine. PMID 32042194 DOI: 10.1038/S41591-019-0749-Z  0.506
2020 Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes ME, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop I, Dillon DA, ... ... Wagle N, et al. Tumor mutational burden and alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32019858 DOI: 10.1158/1078-0432.Ccr-19-3507  0.659
2020 Wagle N, Painter C, Anastasio E, Dunphy M, McGillicuddy M, Jain E, Hernandez TG, Balch S, Thomas B, Kim D, Damon AL, Shah S, Tomson BN, Stoddard R, Nguyen C, et al. Abstract PD8-01: The metastatic breast cancer project: Generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd8-01  0.487
2020 Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia J, Lloyd M, Kim D, Luo F, Mao P, Helvie K, Kowalski K, Nayar U, Parsons S, Martinez R, Litchfield L, ... Wagle N, et al. Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd2-09  0.647
2020 Wander S, Mao P, Lloyd M, Kowalski K, Johnson GN, Malvarosa G, Moy B, Ellisen LW, Iafrate J, Wagle N, Bardia A. Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-08  0.548
2020 Fu X, Pereira R, Angelis CD, Nanda S, Qin L, Shea MJ, Mitchell T, Veeraraghavan J, Sethunath V, Gutierrez C, Győrffy B, Cohen O, Wagle N, Nardone A, Jeselsohn R, et al. Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-04-02  0.405
2020 Barroso-Sousa R, Li T, Trippa L, Rees R, Andrews C, Ferreira AR, Helvie K, Partridge AH, Overmoyer B, Winer EP, Wagle N, Tolaney SM. Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-11-04  0.462
2020 Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo C, Li T, Fleharty M, Kirkner G, Rotem D, Cohen O, Hughes M, Rosenberg S, ... ... Wagle N, et al. Abstract P5-01-03: Ultrasensitive detection of minimal residual disease in patients treated for breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-01-03  0.454
2020 Buendia-Buendia JE, Pernas S, Cohen O, Mao PP, Kowalski K, Lin N, Winer E, Wagle N. Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P3-01-09  0.457
2020 Cohen O, Abravanel D, Slyper M, Klughammer J, Jane-Valbuena J, Helvie K, Dellostritto L, Frangieh A, Vigneau S, Wu J, Mayorga A, Waldman J, Nguyen L, Dionne D, Ashenberg O, ... ... Wagle N, et al. Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-05  0.467
2020 Cohen O, Mao P, Nayar U, Buendia-Bue JE, Kim D, Jain E, Helvie K, Abravanel D, Kowalski KJ, Kapstad C, Freeman S, Adalsteinsson V, Wander SA, Waks AG, Getz G, ... ... Wagle N, et al. Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-02  0.461
2020 Nayar U, Piccioni F, Yang X, Root D, Neal JT, Eli LD, Diala I, Lalani AS, Wagle N. Abstract 1914: Phenotypic characterization of a comprehensive set of HER2 missense mutants in ER+ breast cancer Cancer Research. 80: 1914-1914. DOI: 10.1158/1538-7445.Am2020-1914  0.515
2019 Exman P, Garrido-Castro AC, Hughes ME, Freedman RA, Li T, Trippa L, Bychkovsky BL, Barroso-Sousa R, Di Lascio S, Mackichan C, Lloyd MR, Krevalin M, Cerami E, Merrill MS, Santiago R, ... ... Wagle N, et al. Identifying Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. Jco Precision Oncology. 3. PMID 32923853 DOI: 10.1200/PO.19.00087  0.37
2019 Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, Chamness GC, Feng Q, O'Malley BW, Selenica P, Weigelt B, ... ... Wagle N, et al. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31826955 DOI: 10.1073/Pnas.1911584116  0.436
2019 Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, ... ... Wagle N, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nature Cell Biology. 21: 879-888. PMID 31263265 DOI: 10.1038/S41556-019-0346-X  0.307
2019 Cornell L, Wander SA, Visal T, Wagle N, Shapiro GI. MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Reports. 26: 2667-2680.e7. PMID 30840889 DOI: 10.1016/J.Celrep.2019.02.023  0.409
2019 Waks AG, Jain E, Collins LC, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Come SE, Peppercorn JM, Borges VF, Warner E, Snow C, Partridge AH, Wagle N. Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H). Journal of Clinical Oncology. 37: 554-554. DOI: 10.1200/Jco.2019.37.15_Suppl.554  0.409
2019 Waks AG, Cohen O, Kochupurakkal B, Kim D, Wander SA, Buendia-Buendia J, Helvie K, Matulonis UA, Krop IE, Tolaney SM, Winer EP, D'Andrea AD, Shapiro G, Lin NU, Wagle N. Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC). Journal of Clinical Oncology. 37: 1085-1085. DOI: 10.1200/Jco.2019.37.15_Suppl.1085  0.466
2019 Garrido-Castro AC, Spurr L, Hughes ME, Li YY, Cherniack AD, Bychkovsky BL, Barroso-Sousa R, Lascio SD, Files J, Kumari P, Cerami E, Krop IE, MacConaill LE, Lindeman NI, Rollins BJ, ... ... Wagle N, et al. Genomic landscape of de novo stage IV breast cancer. Journal of Clinical Oncology. 37: 1022-1022. DOI: 10.1200/Jco.2019.37.15_Suppl.1022  0.433
2019 Buendia-Buendia J, Cohen O, Kim D, Jain E, Winer EP, Lin NU, Wagle N. Characterization of mutational processes in ER+ metastatic breast cancer. Journal of Clinical Oncology. 37: 1019-1019. DOI: 10.1200/Jco.2019.37.15_Suppl.1019  0.427
2019 Jain E, Kim D, Buendia J, Cohen O, Sousa R, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Balch S, Thomas B, Lascio SD, Tomson B, Nguyen C, Painter C, Wagle N, et al. Abstract PD9-03: The genomic landscape of de novo metastatic breast cancer (MBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-03  0.525
2019 Cohen O, Buendia-Buendia J, Wander S, Nayar U, Mao P, Waks A, Kim D, Freeman S, Adalsteinsson V, Helvie K, Livitz D, Rosebrock D, Leshchiner I, Dellostritto L, Garrido-Castro A, ... ... Wagle N, et al. Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-02  0.505
2019 Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Lascio SD, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, et al. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-01  0.367
2019 Rosenbluth J, Zervantonakis I, Boedicker M, Wagle N, Dillon D, Nakhlis F, Brugge J, Overmoyer B. Abstract P5-17-01: Patient-derived organoid models of inflammatory breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-17-01  0.413
2019 Zañudo JGT, Mao P, Montero J, Xu G, Kowalski KJ, Johnson GN, Baselga J, Scaltriti M, Letai AG, Wagle N, Albert R. Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-675  0.331
2019 Mao P, Cohen O, Kowalski K, Kusiel J, Buendia J, Exman P, Wander SA, Waks AG, Winer EP, Lin NU, Wagle N. Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-314  0.382
2018 Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, Painter C, Freeman S, Persky NS, Marini L, Helvie K, Oliver N, Rozenblatt-Rosen O, Ma CX, Regev A, ... ... Wagle N, et al. Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics. PMID 30531871 DOI: 10.1038/S41588-018-0287-5  0.707
2018 Hinohara K, Wu HJ, Vigneau S, McDonald TO, Igarashi KJ, Yamamoto KN, Madsen T, Fassl A, Egri SB, Papanastasiou M, Ding L, Peluffo G, Cohen O, Kales SC, Lal-Nag M, ... ... Wagle N, et al. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. PMID 30472020 DOI: 10.1016/J.Ccell.2018.10.014  0.431
2018 Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. PMID 30220708 DOI: 10.1038/S41416-018-0261-0  0.596
2018 Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, et al. Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer. Npj Breast Cancer. 4: 22. PMID 30083595 DOI: 10.1038/s41523-018-0075-5  0.341
2018 Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, ... ... Wagle N, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discovery. PMID 29903880 DOI: 10.1158/2159-8290.Cd-18-0275  0.637
2018 Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. The Oncologist. PMID 29593099 DOI: 10.1634/Theoncologist.2017-0691  0.561
2018 Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, ... ... Wagle N, et al. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 33: 173-186.e5. PMID 29438694 DOI: 10.1016/J.Ccell.2018.01.004  0.424
2018 Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, Choudhury AD, Gydush G, Reed SC, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017760033. PMID 29298117 DOI: 10.1200/Jco.2017.76.0033  0.527
2018 Mullane SA, Painter C, Dunphy M, Anastasio E, Simoncelli T, Zarrelli K, Philippakis A, McKay RR, Choueiri TK, Golub T, Lander E, Wagle N, Van Allen EM. The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement. Journal of Clinical Oncology. 36: 279-279. DOI: 10.1200/Jco.2018.36.6_Suppl.279  0.435
2018 Wagle N, Painter C, Van Allen EM, Bass AJ, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Balch S, Thomas B, Tomson BN, Nguyen C, Jain E, Wankowicz S, Palma J, et al. Count me in: A patient-driven research initiative to accelerate cancer research. Journal of Clinical Oncology. 36: e13501-e13501. DOI: 10.1200/Jco.2018.36.15_Suppl.E13501  0.437
2018 Wander SA, Cohen O, Johnson GN, Kim D, Luo F, Mao P, Nayar U, Helvie K, Marini L, Freeman S, Getz G, Garraway LA, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016. DOI: 10.1200/Jco.2018.36.15_Suppl.12016  0.739
2018 Barroso-Sousa R, Guo H, Barry WT, Ferreira AR, Rees R, Winer EP, Wagle N, Tolaney SM. A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis. Journal of Clinical Oncology. 36: 1068-1068. DOI: 10.1200/Jco.2018.36.15_Suppl.1068  0.333
2018 Waks AG, Tolaney SM, Schnitt SJ, Dillon D, Gjini E, Abdelrahman S, Marino-Enriquez A, Helvie K, Marini L, Cohen O, Kim D, Wander SA, Stover DG, Rodig S, Krop IE, ... ... Wagle N, et al. The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received. Journal of Clinical Oncology. 36: 1054-1054. DOI: 10.1200/Jco.2018.36.15_Suppl.1054  0.414
2018 Barroso-Sousa R, Jain E, Kim D, Partridge AH, Cohen O, Wagle N. Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer. Journal of Clinical Oncology. 36: 1010-1010. DOI: 10.1200/Jco.2018.36.15_Suppl.1010  0.43
2018 Mao P, Kusiel J, Cohen O, Wagle N. Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd4-01  0.482
2018 Dunphy M, Jain E, Anastasio E, McGillicuddy M, Stoddard R, Thomas B, Balch S, Anderka K, Larkin K, Lennon N, Chen Y, Zimmer A, Baker EO, Maiwald S, Lapan JH, ... ... Wagle N, et al. Abstract 5384: The Angiosarcoma Project: Generating the genomic landscape of an exceedingly rare cancer through a nationwide patient-driven initiative Cancer Research. 78: 5384-5384. DOI: 10.1158/1538-7445.Am2018-5384  0.495
2018 Wagle N, Painter C, Anastasio E, Dunphy M, McGillicuddy M, Stoddard R, Jain E, Kim D, Lascio SD, Tompson BN, Balch S, Thomas B, Kumari P, Johnson S, Holloway J, et al. Abstract 5371: The Metastatic Breast Cancer Project: Partnering with patients to accelerate progress in cancer research Cancer Research. 78: 5371-5371. DOI: 10.1158/1538-7445.Am2018-5371  0.469
2018 Nayar U, Cohen O, Kapstad C, Waks A, Wander SA, Painter C, Freeman S, Ram P, Persky N, Marini L, Helvie K, Oliver N, Ma CX, Winer EP, Lin NU, ... Wagle N, et al. Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies Cancer Research. 78: 4952-4952. DOI: 10.1158/1538-7445.Am2018-4952  0.499
2018 Mo SS, Liu D, Gray SW, Joffe S, Wagle N, Garber J, Garraway LA, Sholl L, Janne PA, Allen EMV. Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer Cancer Research. 78: 3254-3254. DOI: 10.1158/1538-7445.Am2018-3254  0.662
2017 Sanghvi RV, Buhay CJ, Powell BC, Tsai EA, Dorschner MO, Hong CS, Lebo MS, Sasson A, Hanna DS, McGee S, Bowling KM, Cooper GM, Gray DE, Lonigro RJ, Dunford A, ... ... Wagle N, et al. Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 29144510 DOI: 10.1038/Gim.2017.192  0.566
2017 Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, ... ... Wagle N, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications. 8: 1324. PMID 29109393 DOI: 10.1038/S41467-017-00965-Y  0.741
2017 Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993  0.737
2017 McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW. The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine. 14: 37-50. PMID 28757884 DOI: 10.2217/Pme-2016-0074  0.673
2017 Ladas I, Fitarelli-Kiehl M, Song C, Adalsteinsson VA, Parsons HA, Lin NU, Wagle N, Makrigiorgos GM. Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. Clinical Chemistry. PMID 28679646 DOI: 10.1373/Clinchem.2017.272849  0.366
2017 Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, et al. Systematic genomic and translational efficiency studies of uveal melanoma. Plos One. 12: e0178189. PMID 28594900 DOI: 10.1371/Journal.Pone.0178189  0.689
2017 Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, ... ... Wagle N, et al. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 28125075 DOI: 10.1038/Gim.2016.191  0.708
2017 Mullane SA, Painter C, Dunphy M, Anastasio E, Simoncelli T, Zarrelli K, Philippakis A, McKay RR, Choueiri TK, Golub T, Lander E, Wagle N, Van Allen EM. The Prostate Cancer Project (PC Project): Translational genomics through direct patient engagement. Journal of Clinical Oncology. 35: 199-199. DOI: 10.1200/Jco.2017.35.6_Suppl.199  0.431
2017 Painter C, Dunphy M, Anastasio E, McGillicuddy M, Anderka K, Larkin K, Lennon N, Chen Y, Lander E, Golub T, Wagle N. The Angiosarcoma Project: Generating the genomic landscape of a rare cancer through a direct-to-patient initiative. Journal of Clinical Oncology. 35: 1519-1519. DOI: 10.1200/Jco.2017.35.15_Suppl.1519  0.386
2017 Stover DG, Parsons HA, Ha G, Freeman S, Barry WT, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes ME, Krop IE, Tolaney SM, Wagle N, Getz G, et al. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal of Clinical Oncology. 35: 1092-1092. DOI: 10.1200/Jco.2017.35.15_Suppl.1092  0.508
2017 Wagle N, Painter C, Anastasio E, Dunphy M, McGillicuddy M, Kim D, Jain E, Buendia-Buendia J, Cohen O, Knelson E, Holloway J, Johnson S, Larkin K, Adalsteinsson V, Ha G, et al. The Metastatic Breast Cancer (MBC) project: Accelerating translational research through direct patient engagement. Journal of Clinical Oncology. 35: 1076-1076. DOI: 10.1200/Jco.2017.35.15_Suppl.1076  0.421
2017 Luis IMVD, Guo H, Barry WT, Krop IE, Wagle N, Lowe A, Gore D, Andrews C, Osmani W, Isakoff SJ, Tung NM, Winer EP, Lin NU, Freedman RA. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 35: 1034-1034. DOI: 10.1200/Jco.2017.35.15_Suppl.1034  0.351
2017 Tseng Y(, Hong A, Gill S, Keskula P, Raghavan S, Cheah J, Tsherniak A, Vazquez F, Alkhairy S, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, Garraway L, ... ... Wagle N, et al. Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A02  0.616
2017 Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, ... Wagle N, et al. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S1-01  0.631
2017 Nayar U, Cohen O, Oh C, Wagle N. Abstract P3-04-08: The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-04-08  0.527
2017 Mao P, Quartey Q, Cohen O, Piccioni F, Wagle N. Abstract P3-03-08: A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-08  0.45
2017 Kuang Y, Siddiqui B, Hu J, Barry WT, Lin NU, Wagle N, Kirschmeier P, Jänne PA, Paweletz C, Krop I, Winer EP, Brown M, Jeselsohn R. Abstract 4950: The emergence of ESR1 mutations is associated with aromatase inhibitor and fulvestrant therapy Cancer Research. 77: 4950-4950. DOI: 10.1158/1538-7445.Am2017-4950  0.44
2017 Aguirre AJ, Carter S, Camarda N, Ghazani A, Nowak J, Silva AD, Brais L, Ragon D, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Shyn P, ... ... Wagle N, et al. Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine Cancer Research. 77: 3036-3036. DOI: 10.1158/1538-7445.Am2017-3036  0.561
2017 Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Alkhairy S, Oh C, Peng A, Deasy R, Sayeed A, Ronning P, ... ... Wagle N, et al. Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models Cancer Research. 77: 1953-1953. DOI: 10.1158/1538-7445.Am2017-1953  0.536
2016 Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, ... ... Wagle N, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine. 8: 79. PMID 27460824 DOI: 10.1186/S13073-016-0333-9  0.719
2016 Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Wagle N, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. 99: 246. PMID 27392080 DOI: 10.1016/J.Ajhg.2016.06.002  0.535
2016 Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Wagle N, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. PMID 27181682 DOI: 10.1016/J.Ajhg.2016.04.011  0.571
2016 Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26866579 DOI: 10.1038/Gim.2015.207  0.699
2016 Wagle N, Painter C, Krevalin M, Oh C, Anderka K, Larkin K, Lennon N, Dillon D, Frank E, Winer EP, Lander E, Golub T. The Metastatic Breast Cancer Project: A national direct-to-patient initiative to accelerate genomics research. Journal of Clinical Oncology. 34: LBA1519-LBA1519. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba1519  0.49
2016 McGraw SA, Joffe S, Garber JE, Janne PA, Lindeman NI, Oliver N, Sholl LM, Allen EMV, Wagle N, Garraway LA, Gray SW. Deliberations of a precision medicine tumor board. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E13005  0.624
2016 Waks AG, Cohen O, Helvie K, Lloyd MR, Marini L, Oh C, Oliver N, Lindeman NI, Matulonis UA, Krop IE, Garraway LA, Winer EP, Lin NU, Wagle N. Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). Journal of Clinical Oncology. 34: 542-542. DOI: 10.1200/Jco.2016.34.15_Suppl.542  0.623
2016 Garofalo A, Sholl LM, Reardon B, Amin-Mansour A, Miao D, Liu D, Oliver N, Ghazani AA, Gray SW, Janne PA, Garber JE, Joffe S, Lindeman NI, Garraway LA, Wagle N, et al. Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. Journal of Clinical Oncology. 34: 1500-1500. DOI: 10.1200/Jco.2016.34.15_Suppl.1500  0.63
2016 Ghazani AA, Oliver N, Pierre JPS, Garofalo A, Sholl LM, Lindeman NI, Garber JE, Joffe S, Janne PA, Gray SW, Garraway LA, Allen EMV, Wagle N. Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. Journal of Clinical Oncology. 34: 11565-11565. DOI: 10.1200/Jco.2016.34.15_Suppl.11565  0.65
2016 Wagle N, Helvie K, Lloyd MR, Marini L, Waks AG, Cohen O, Oh C, Sougnez C, Oliver N, Quartey Q, Rotem A, Shah P, Lindeman NI, Krop IE, Garraway LA, et al. A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. Journal of Clinical Oncology. 34: 11513-11513. DOI: 10.1200/Jco.2016.34.15_Suppl.11513  0.605
2016 Tseng Y, Keskula P, Hong AL, Gill S, Cheah JH, Kryukov GV, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... ... Wagle N, et al. Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B26  0.62
2016 Formisano L, Young C, Bhola N, Bulen B, Estrada V, Wagle N, Allen EV, Brewer MR, Jansen V, Guerrero A, Giltnane J, Strcker T, Arteaga C. Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S3-03  0.312
2016 Wagle N, Painter C, Ilzarbe M, Allen EV, Frank E, Oh C, Krevalin M, Lloyd M, Anderka K, Kryukov G, Boehm J, Winer E, Lander E, Golub T. Abstract OT2-05-03: The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Ot2-05-03  0.422
2016 Adalsteinsson VA, Ha G, Freeman S, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed S, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Cohen O, Oh C, Kim J, ... Wagle N, et al. Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-136  0.679
2016 Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, ... ... Wagle N, et al. Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Cancer Research. 76: 4367-4367. DOI: 10.1158/1538-7445.Am2016-4367  0.629
2015 Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, ... Wagle N, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Jama Oncology. 1: 238-44. PMID 26181029 DOI: 10.1001/Jamaoncol.2015.34  0.65
2015 Kwiatkowski DJ, Wagle N. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? Ebiomedicine. 2: 2-4. PMID 26137524 DOI: 10.1016/J.Ebiom.2014.12.011  0.506
2015 Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, et al. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs. PMID 26123926 DOI: 10.1007/S10637-015-0269-8  0.63
2015 Stover DG, Wagle N. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Current Oncology Reports. 17: 15. PMID 25708799 DOI: 10.1007/S11912-015-0438-0  0.516
2015 Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67. PMID 25673644 DOI: 10.1158/2159-8290.Cd-14-1518  0.748
2015 Luis IMVD, Oh C, Wang Z, Dipiro P, Macrae EM, Painter C, Kryukov G, Krop IE, Winer EP, Lin NU, Wagle N. Whole exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). Journal of Clinical Oncology. 33: 611-611. DOI: 10.1200/Jco.2015.33.15_Suppl.611  0.439
2015 Goetz EM, Ghandi M, Treacy D, Wagle N, Garraway LA. Abstract PR02: Identification of ERK1/2 mutations that confer resistance to MAPK pathway inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr02  0.592
2015 Grabiner B, Wagle N, Allen EV, Garraway L, Lorch J, Sabatini D. Abstract PR04: mTOR mutations in cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Pr04  0.666
2015 Place CS, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, et al. Abstract A1-15: Systematic genomic characterization of uveal melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-15  0.622
2015 Giltnane JM, Balko JM, Stricker TL, Young C, Estrada MV, Wagle N, Allen Ev, Mu XJ, Sanchez V, Farley J, Fitzgerald K, Graber A, Pinto JA, Doimi F, Gómez H, et al. Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-3  0.637
2015 Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Bose R, Shen W, Wolff AC, et al. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd3-5  0.613
2015 Corcoran RB, Ahronian LG, Allen EV, Coffee EM, Wagle N, Kwak EL, Faris JE, Iafrate AJ, Garraway LA, Engelman JA. Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ng04  0.626
2014 Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, ... ... Wagle N, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: E5564-73. PMID 25512523 DOI: 10.1073/Pnas.1419260111  0.82
2014 Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Research. 74: 7079-89. PMID 25320010 DOI: 10.1158/0008-5472.Can-14-2073  0.57
2014 Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. The New England Journal of Medicine. 371: 1426-33. PMID 25295501 DOI: 10.1056/Nejmoa1403352  0.731
2014 Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 4: 1140-53. PMID 25096233 DOI: 10.1158/2159-8290.Cd-14-0623  0.685
2014 Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology. 32: 644-52. PMID 24952901 DOI: 10.1038/Nbt.2940  0.729
2014 Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer. 13: 141. PMID 24894453 DOI: 10.1186/1476-4598-13-141  0.432
2014 Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine. 20: 682-8. PMID 24836576 DOI: 10.1038/Nm.3559  0.71
2014 Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discovery. 4: 546-53. PMID 24625776 DOI: 10.1158/2159-8290.Cd-13-0353  0.711
2014 Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy Prostate Cancer and Prostatic Diseases. 17: 23-27. PMID 24366412 DOI: 10.1038/Pcan.2013.37  0.519
2014 Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery. 4: 61-8. PMID 24265154 DOI: 10.1158/2159-8290.Cd-13-0631  0.709
2014 Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, Mckenna A, Cibulskis K, Farlow D, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discovery. 4: 94-109. PMID 24265153 DOI: 10.1158/2159-8290.Cd-13-0617  0.721
2014 Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Investigational New Drugs. 32: 178-187. PMID 24242861 DOI: 10.1007/S10637-013-0045-6  0.716
2014 Freedman RA, Luis IMVD, Barry WT, Krop IE, Wagle N, Lowe A, Galler S, Sohl J, Isakoff SJ, Tung NM, Winer EP, Lin NU. A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps668  0.387
2014 Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Wolff AC, Gabriel SB, Garraway LA, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. Journal of Clinical Oncology. 32: 536-536. DOI: 10.1200/Jco.2014.32.15_Suppl.536  0.654
2014 Rosenberg JE, Van Allen EM, Mouw KW, Kim PH, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Iyer G, Signoretti S, Reuter VE, Getz G, Kantoff PW, Bochner BH, Choueiri TK, et al. Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Journal of Clinical Oncology. 32: 4510-4510. DOI: 10.1200/Jco.2014.32.15_Suppl.4510  0.578
2014 Gray SW, Wagle N, Garber JE, Rainville IR, Hiller E, Martins Y, Oliver N, Lowenstein C, Najita JS, VanAllen E, Janne PA, Sholl LM, Lindeman NI, Garraway LA, Joffe S. Cancer patients’ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. Journal of Clinical Oncology. 32: 1535-1535. DOI: 10.1200/Jco.2014.32.15_Suppl.1535  0.573
2014 Tolaney SM, Guo H, Barry WT, Larrabee K, Brock JE, Wagle N, Allen EMV, Paweletz C, Ivanova E, Janne PA, Overmoyer B, Wright JJ, Shapiro G, Winer EP, Krop IE. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. Journal of Clinical Oncology. 32: 1106-1106. DOI: 10.1200/Jco.2014.32.15_Suppl.1106  0.411
2014 Kiezun A, Perry J, Tonzi P, Allen EV, Carter SL, Baca S, Bhatt A, Lawrence M, Walensky L, Wagle N, Mora J, deTorres C, Lavarino C, Velasco-Hidalgo L, Cardenas-Cardos R, et al. Abstract A41: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A41  0.799
2014 Mu XJ, Allen EV, Wagle N, Chong C, Butaney M, Farlow D, Getz G, Jänne PA, Garraway LA. Abstract 2371: Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors Cancer Research. 74: 2371-2371. DOI: 10.1158/1538-7445.Am2014-2371  0.632
2014 Wagle N, Grabiner BC, Allen EMV, Amin-Mansour A, Carter SC, Gray N, Barletta JA, Swanson SJ, Ruan D, Kwiatkowski DJ, Hanna GJ, Haddad RI, Sabatini D, Janne PA, Garraway LA, et al. Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma Cancer Research. 74: 1724-1724. DOI: 10.1158/1538-7445.Am2014-1724  0.663
2014 Berg JS, Amendola LM, Eng C, Allen EV, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Erratum: Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the clinical sequencing exploratory research consortium (Genetics in Medicine (2013) 15 (860-867) DOI:10.1038/gim.2013.133) Genetics in Medicine. 16. DOI: 10.1038/Gim.2013.191  0.549
2014 Corcoran R, Coffee E, van Allen E, Ahronian L, Wagle N, Kwak E, Faris J, Iafrate A, Garraway L, Engelman J. 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations European Journal of Cancer. 50: 141. DOI: 10.1016/S0959-8049(14)70554-4  0.579
2014 Mouw K, Van Allen E, O’Connor K, Wagle N, Kim P, Al-Ahmadie H, Zhu C, Ostravnaya I, Iyer G, Signoretti S, Reuter V, Getz G, Kantoff P, Bochner B, Choueiri T, et al. Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S88. DOI: 10.1016/J.Ijrobp.2014.05.481  0.557
2013 Berg JS, Amendola LM, Eng C, Van Allen E, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 860-7. PMID 24195999 DOI: 10.1038/Gim.2013.133  0.68
2013 Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 119: 3776-83. PMID 24037752 DOI: 10.1002/Cncr.28288  0.421
2013 Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clinical Breast Cancer. 13: 254-63. PMID 23829891 DOI: 10.1016/J.Clbc.2013.02.010  0.387
2013 Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1825-33. PMID 23589549 DOI: 10.1200/Jco.2013.48.7215  0.665
2013 Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, Wagle N, Abel GA, Rodig SJ, Antin JH, Weinstock DM. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 27: 968-71. PMID 23370706 DOI: 10.1038/Leu.2013.30  0.366
2013 Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discovery. 3: 350-62. PMID 23288408 DOI: 10.1158/2159-8290.Cd-12-0470  0.709
2013 Wagle N, Allen EMV, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. Journal of Clinical Oncology. 31: 9015-9015. DOI: 10.1200/Jco.2013.31.15_Suppl.9015  0.579
2013 Lorch JH, Busaidy N, Ruan DT, Janne PA, Limaye SA, Wirth LJ, Barletta JA, Rabinowits G, Garraway LA, Allen EMV, Wagle N, Hanna GJ, Misiukiewicz K, Suda M, Haddad TC, et al. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). Journal of Clinical Oncology. 31: 6023-6023. DOI: 10.1200/Jco.2013.31.15_Suppl.6023  0.493
2013 Rollins BJ, MacConaill LE, Wagle N, Garcia E, Kuo FC, Longtine JA, Garber JE, Janeway KA, Fuchs CS, Bertagnolli MM, Soiffer R, Matulonis U, Lin NU, Hahn WC, Garraway LA, et al. PROFILE: Broadly based genomic testing for all patients at a major cancer center. Journal of Clinical Oncology. 31: 1531-1531. DOI: 10.1200/Jco.2013.31.15_Suppl.1531  0.616
2013 Allen EMV, Wagle N, Carter SL, Sucker A, Farlow DN, Hodis E, Taylor-Weiner A, Berking C, Egberts F, Hassel JC, Gogas H, Gutzmer R, Goldinger SM, Loquai C, Ugurel S, et al. The genetic landscape of clinical resistance to RAF inhibition in melanoma. Journal of Clinical Oncology. 31: 11009-11009. DOI: 10.1200/Jco.2013.31.15_Suppl.11009  0.617
2013 Rodon J, Juric D, Gonzalez-Angulo A, Bendell J, Berlin J, Bootle D, Gravelin K, Huang A, Derti A, Lehar J, Würthner J, Boehm M, Allen Ev, Wagle N, Garraway LA, et al. Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-65  0.661
2013 Hummelen PV, Ducar M, Jones RT, Raza A, Sunkavalli A, Hanna M, Mills A, Adusumilli R, Kumar P, Schubert L, Breneiser M, Cooley AC, Garcia E, Scholl LM, Lindeman NI, ... Wagle N, et al. Abstract 819: Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. Cancer Research. 73: 819-819. DOI: 10.1158/1538-7445.Am2013-819  0.657
2013 Wagle N, Allen EV, Perrin D, Friedrich D, Fisher S, Kryukov G, Ambrogio L, Auclair D, Gray S, Joffe S, Janne P, Garber J, Macconaill L, Lindeman N, Rollins B, et al. Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. Cancer Research. 73: 3152-3152. DOI: 10.1158/1538-7445.Am2013-3152  0.654
2013 Allen EMV, Wagle N, Keizun A, Kryukov G, McKenna A, Huang F, Hiller E, Rainville I, Auclair D, Ambrogio L, Gray S, Joffe S, Getz G, Garber J, Garraway L. Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. Cancer Research. 73: 2570-2570. DOI: 10.1158/1538-7445.Am2013-2570  0.634
2012 Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Molecular Cancer Therapeutics. 11: 2301-5. PMID 22879364 DOI: 10.1158/1535-7163.Mct-12-0511  0.643
2012 Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, ... ... Wagle N, et al. A landscape of driver mutations in melanoma. Cell. 150: 251-63. PMID 22817889 DOI: 10.1016/J.Cell.2012.06.024  0.563
2012 Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, ... Wagle N, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 485: 502-6. PMID 22622578 DOI: 10.1038/Nature11071  0.608
2012 Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB, Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery. 2: 82-93. PMID 22585170 DOI: 10.1158/2159-8290.CD-11-0184  0.618
2012 Wright AA, Hirsch MS, Wagle N, Howitt BE, Palescandolo E, MacConaill LE, Hummelen PV, Shoni M, Hahn WC, Matulonis UA. KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix. Journal of Clinical Oncology. 30: 5011-5011. DOI: 10.1200/Jco.2012.30.15_Suppl.5011  0.476
2012 Allen EMV, Wagle N, Kryukov G, Ramos A, Getz G, Garraway LA. A heuristic platform for clinical interpretation of cancer genome sequencing data. Journal of Clinical Oncology. 30: 10502-10502. DOI: 10.1200/Jco.2012.30.15_Suppl.10502  0.605
2012 Whittaker S, Hodis E, Wagle N, Hsiao J, Cowley G, Root D, Garraway L. Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-B20  0.597
2012 Vaz-Luis I, Seah D, Olson E, Metzger O, Wagle N, Sohl J, Litsas G, Burstein H, Krop I, Winer E, Lin N. Abstract P5-18-03: Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-18-03  0.372
2011 Wagle N, Berger MF, Davis MJ, Blumenstiel B, DeFelice M, Hahn WC, Meyerson M, Gabriel SB, MacConaill LE, Garraway LA. Tumor genomic profiling of FFPE samples by massively parallel sequencing. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10502. PMID 28022364 DOI: 10.1200/Jco.2011.29.15_Suppl.10502  0.59
2011 Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3085-96. PMID 21383288 DOI: 10.1200/Jco.2010.33.2312  0.651
2011 Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling Cancer Research. 71: 3933-3933. DOI: 10.1158/1538-7445.Am2011-3933  0.667
2011 Miller T, Fox E, Balko J, Meszoely I, Sanders M, Kuba M, Wagle N, Garraway L, Maira S, Arteaga C. S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S3-4  0.627
2010 Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. American Journal of Clinical Pathology. 134: 478-90. PMID 20716806 DOI: 10.1309/Ajcp2Y8Ktdpoaorh  0.364
2010 Wagle N, Davis M, Berger MF, Blumenstiel B, Defelice M, Hahn W, Meyerson M, Gabriel SB, MacConaill L, Garraway LA. Abstract LB-122: High-throughput tumor genomic profiling by massively parallel sequencing Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-122  0.659
2003 Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A. A p53-dependent checkpoint pathway prevents rereplication. Molecular Cell. 11: 997-1008. PMID 12718885 DOI: 10.1016/S1097-2765(03)00099-6  0.329
2001 Goldman DP, Schoenbaum ML, Potosky AL, Weeks JC, Berry SH, Escarce JJ, Weidmer BA, Kilgore ML, Wagle N, Adams JL, Figlin RA, Lewis JH, Cohen J, Kaplan R, McCabe M. Measuring the incremental cost of clinical cancer research Journal of Clinical Oncology. 19: 105-110. PMID 11134202 DOI: 10.1200/Jco.2001.19.1.105  0.327
2001 Schoenbaum M, Kilgore ML, Weidmer BA, Berry SH, Escarce JJ, Goldman DP, Lewis JH, Wagle N. Using hospital tumor registries to identify research subjects Health Services and Outcomes Research Methodology. 2: 67-76. DOI: 10.1023/A:1011432302562  0.414
Show low-probability matches.